Literature DB >> 20656297

Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis.

Kim M Hare1, Keith Grimwood, Amanda J Leach, Heidi Smith-Vaughan, Paul J Torzillo, Peter S Morris, Anne B Chang.   

Abstract

OBJECTIVE: To test the hypothesis that bacterial density, strain diversity, and concordance of pathogens between upper and lower airways are higher in children with bronchiectasis than in those with non-bronchiectatic conditions. STUDY
DESIGN: Nasopharyngeal (NP) swabs and bronchoalveolar lavage (BAL) fluid were cultured from 45 Indigenous children with bronchiectasis and 30 non-Indigenous children with non-bronchiectatic respiratory symptoms. Lower airway infection was defined as >10(4) colony-forming units of respiratory bacteria/mL of BAL fluid. Concordance was determined by phenotype or genotype.
RESULTS: NP carriage of Streptococcus pneumoniae, nontypable Haemophilus influenzae (NTHi), and Moraxella catarrhalis, and lower airway infection by NTHi (47% vs 3%), were detected significantly more often in the children with bronchiectasis than in those without this condition. BAL specimens from the infected Indigenous children also showed greater strain diversity (71% vs 0%). Strain concordance in NP and BAL cultures was high in both infected subgroups.
CONCLUSIONS: The high density and diversity of respiratory bacteria, along with strain concordance between upper and lower airways, found in Indigenous children with bronchiectasis suggest a possible pathogenic role of recurrent aspiration of NP secretions.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20656297     DOI: 10.1016/j.jpeds.2010.06.002

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  40 in total

1.  Metabolomic profiles of plasma, exhaled breath condensate, and saliva are correlated with potential for air toxics detection.

Authors:  Chandresh Nanji Ladva; Rachel Golan; Roby Greenwald; Tianwei Yu; Stefanie Ebelt Sarnat; W Dana Flanders; Karan Uppal; Douglas I Walker; ViLinh Tran; Donghai Liang; Dean P Jones; Jeremy A Sarnat
Journal:  J Breath Res       Date:  2017-12-06       Impact factor: 3.262

2.  Response to "Bacteria from bronchoalveolar lavage fluid from children with suspected chronic lower respiratory tract infection: results from a multi-center, cross-sectional study in Spain" Eur J Pediatr (2018) 177:181-192.

Authors:  Kim M Hare; Keith Grimwood; Anne B Chang
Journal:  Eur J Pediatr       Date:  2018-06-14       Impact factor: 3.183

3.  Culture and PCR detection of Haemophilus influenzae and Haemophilus haemolyticus in Australian Indigenous children with bronchiectasis.

Authors:  K M Hare; M J Binks; K Grimwood; A B Chang; A J Leach; H Smith-Vaughan
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

4.  Absence of an important vaccine and diagnostic target in carriage- and disease-related nontypeable Haemophilus influenzae.

Authors:  Heidi C Smith-Vaughan; Anne B Chang; Derek S Sarovich; Robyn L Marsh; Keith Grimwood; Amanda J Leach; Peter S Morris; Erin P Price
Journal:  Clin Vaccine Immunol       Date:  2013-11-27

5.  Could vitamin d have a potential anti-inflammatory and anti-infective role in bronchiectasis?

Authors:  Jim Bartley; Jeff Garrett; Cameron C Grant; Carlos A Camargo
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

6.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

Authors:  Michael M Tunney; Gisli G Einarsson; Lan Wei; Maire Drain; Erich R Klem; Chris Cardwell; Madeleine Ennis; Richard C Boucher; Matthew C Wolfgang; J Stuart Elborn
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

7.  Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo.

Authors:  K M Hare; K Grimwood; A B Chang; M D Chatfield; P C Valery; A J Leach; H C Smith-Vaughan; P S Morris; C A Byrnes; P J Torzillo; A C Cheng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-12       Impact factor: 3.267

8.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

9.  Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Keith Grimwood; Paul J Torzillo; Catherine A Byrnes; I Brent Masters; Paul A Bauert; Gabrielle B McCallum; Charmaine Mobberly; Anne B Chang
Journal:  BMC Pediatr       Date:  2012-08-14       Impact factor: 2.125

10.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.